MCID: PRD006
MIFTS: 63

Prader-Willi Syndrome malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Reproductive diseases, Endocrine diseases, Fetal diseases

Aliases & Classifications for Prader-Willi Syndrome

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 23GeneReviews, 24GeneTests, 25Genetics Home Reference, 27GTR, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 38MedlinePlus, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet, 71Wikipedia
See all MalaCards sources

Aliases & Descriptions for Prader-Willi Syndrome:

Name: Prader-Willi Syndrome 52 11 71 23 48 24 25 54 12 50 38 39 13
Prader-Labhart-Willi Syndrome 23 48 24 25 54
Willi-Prader Syndrome 48 25 54 27
 
Pws 23 48 24 25
Prader Willi Syndrome 11

Characteristics:

Orphanet epidemiological data:

54
prader-willi syndrome:
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: Antenatal,Neonatal; Age of death: normal life expectancy

HPO:

64
prader-willi syndrome:
Inheritance: sporadic

GeneReviews:

23
Penetrance: penetrance is complete...


Classifications:



External Ids:

OMIM52 176270
Disease Ontology11 DOID:11983
ICD1030 Q87.1
ICD9CM32 759.81
MeSH39 D011218
SNOMED-CT62 205794007, 89392001
NCIt45 C75463
Orphanet54 ORPHA739
MESH via Orphanet40 D011218
UMLS via Orphanet69 C0032897
ICD10 via Orphanet31 Q87.1

Summaries for Prader-Willi Syndrome

About this section
MedlinePlus:38 Prader-willi syndrome (pws) is a rare genetic disorder. it causes poor muscle tone, low levels of sex hormones and a constant feeling of hunger. the part of the brain that controls feelings of fullness or hunger does not work properly in people with pws. they overeat, leading to obesity. babies with pws are usually floppy, with poor muscle tone, and have trouble sucking. boys may have undescended testicles. later, other signs appear. these include short stature poor motor skills weight gain underdeveloped sex organs mild intellectual and learning disabilities there is no cure for pws. growth hormone, exercise, and dietary supervision can help build muscle mass and control weight. other treatments may include sex hormones and behavior therapy. most people with pws will need specialized care and supervision throughout their lives. nih: national institute of child health and human development

MalaCards based summary: Prader-Willi Syndrome, also known as prader-labhart-willi syndrome, is related to prader-willi syndrome due to imprinting mutation and obesity, and has symptoms including hypogonadotrophic hypogonadism, delayed speech and language development and infertility. An important gene associated with Prader-Willi Syndrome is NDN (Necdin, MAGE Family Member), and among its related pathways are Synaptic Neurotransmission Pathways: GABAergic Inhibition and Gastric cancer network 2. Affiliated tissues include skin, brain and testes, and related mouse phenotypes are adipose tissue and behavior/neurological.

Genetics Home Reference:25 Prader-Willi syndrome is a complex genetic condition that affects many parts of the body. In infancy, this condition is characterized by weak muscle tone (hypotonia), feeding difficulties, poor growth, and delayed development. Beginning in childhood, affected individuals develop an insatiable appetite, which leads to chronic overeating (hyperphagia) and obesity. Some people with Prader-Willi syndrome, particularly those with obesity, also develop type 2 diabetes mellitus (the most common form of diabetes).

OMIM:52 Prader-Willi syndrome is characterized by diminished fetal activity, obesity, muscular hypotonia, mental retardation,... (176270) more...

NIH Rare Diseases:48 Prader-Willi syndrome (PWS) is a genetic condition that affects many parts of the body. Infants with PWS have severe hypotonia (low muscle tone), feeding difficulties, and slow growth. In later infancy or early childhood, affected children typically begin to eat excessively and become obese. Other signs and symptoms often include short stature, hypogonadism, developmental delays, cognitive impairment, and distinctive behavioral characteristics such as temper tantrums, stubbornness, and obsessive-compulsive tendencies. PWS is caused by missing or non-working genes on chromosome 15. Most cases are not inherited and occur randomly. Rarely, a genetic change responsible for PWS can be inherited. Management of PWS generally depends on the affected person's age and symptoms. Last updated: 7/7/2016

Wikipedia:71 Prader–Willi syndrome (PWS) is a genetic disorder due to loss of function of specific genes on... more...

GeneReviews for NBK1330

Related Diseases for Prader-Willi Syndrome

About this section

Diseases in the Prader-Willi Syndrome family:

Prader-Willi Syndrome Due to Paternal Deletion of 15q11q13 Type 1 Prader-Willi Syndrome Due to Paternal Deletion of 15q11q13 Type 2
Prader-Willi Syndrome Due to Translocation Prader-Willi Syndrome Due to Imprinting Mutation
Prader-Willi-Like Syndrome Due to Point Mutation Prader-Willi Syndrome Due to Paternal 15q11q13 Deletion
Prader-Willi Syndrome Due to Maternal Uniparental Disomy of Chromosome 15

Diseases related to Prader-Willi Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 114)
idRelated DiseaseScoreTop Affiliating Genes
1prader-willi syndrome due to imprinting mutation34.1MAGEL2, NDN, SNRPN
2obesity30.9GHRL, IGF1, LEP, MAGEL2, PYY
3angelman syndrome27.9GABRA5, GABRB3, GH1, GHRL, IGF1, IPW
4prader-willi syndrome due to paternal deletion of 15q11q13 type 112.1
5prader-willi syndrome due to paternal deletion of 15q11q13 type 212.1
6prader-willi syndrome due to translocation12.1
7prader-willi syndrome due to paternal 15q11q13 deletion12.1
8prader-willi syndrome due to maternal uniparental disomy of chromosome 1512.1
9schaaf-yang syndrome11.8
10prader-willi habitus, osteopenia, and camptodactyly11.2
11myopathic intestinal pseudoobstruction10.7MAGEL2, NDN, SNRPN
12antenatal multiminicore disease with arthrogryposis multiplex congenita10.6MAGEL2, NDN, SNRPN
13glycogen storage disease due to glucose-6-phosphatase deficiency10.6MAGEL2, NDN, SNRPN
14proton-pump inhibitor-responsive esophageal eosinophilia10.6SNRPN, UBE3A
15severe hemophilia b10.5IGF1, MKRN3
16scoliosis10.4
17cetp-related hyperalphalipoproteinemia10.4IGF1, MKRN3
18hypotonia10.4
19morbid obesity10.4
20dysthymic disorder10.4GHRL, LEP, PYY
21neuronitis10.4
22lymphosarcoma10.4GHRL, LEP, PYY
23mucolipidoses10.3GHRL, LEP, PYY
24hypogonadism10.3
25sleep disorder10.3
26gestational choriocarcinoma10.3GHRL, IGF1, LEP
27autism spectrum disorder10.3
28alveoli adenoma10.3GHRL, IGF1, LEP
29reardon wilson cavanagh syndrome10.3IGF1, LEP
30dyserythropoietic anemia, congenital, type iii10.3NPAP1, UBE3A
31survival motor neuron spinal muscular atrophy10.3GHRL, IGF1, LEP
32sleep apnea10.3
33growth hormone deficiency10.3
34protein s deficiency10.2GH1, GHRL, IGF1
35obstructive sleep apnea10.2
36down syndrome10.2
37epilepsy10.2
38thyroiditis10.2
39precocious puberty10.2
40hypersomnia10.2
41idiopathic generalized epilepsy10.2GABRA5, GABRB3, NIPA2
42growth hormone insensitivity, partial10.2GH1, IGF1
43fragile x syndrome10.1
44cerebritis10.1
45mosaic trisomy 1510.1
46tropical sprue10.1GHRL, IGF1, LEP, PYY
47lung cancer susceptibility 210.1GH1, IGF1, LEP
48angiomatous meningioma10.1GHRL, IGF1, LEP, PYY
49central retinal vein occlusion10.1GH1, IGF1
50insulin-like growth factor i10.1

Graphical network of the top 20 diseases related to Prader-Willi Syndrome:



Diseases related to prader-willi syndrome

Symptoms & Phenotypes for Prader-Willi Syndrome

About this section

Symptoms by clinical synopsis from OMIM:

176270

Clinical features from OMIM:

176270

Human phenotypes related to Prader-Willi Syndrome:

 64 54 (show all 97)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypogonadotrophic hypogonadism64 54 hallmark (90%) Frequent (79-30%) HP:0000044
2 delayed speech and language development64 hallmark (90%) HP:0000750
3 infertility64 hallmark (90%) HP:0000789
4 growth hormone deficiency64 hallmark (90%) HP:0000824
5 global developmental delay64 54 hallmark (90%) Frequent (79-30%) HP:0001263
6 motor delay64 hallmark (90%) HP:0001270
7 generalized hypotonia64 hallmark (90%) HP:0001290
8 specific learning disability64 54 hallmark (90%) Frequent (79-30%) HP:0001328
9 obesity64 54 hallmark (90%) Frequent (79-30%) HP:0001513
10 failure to thrive in infancy64 hallmark (90%) HP:0001531
11 short foot64 hallmark (90%) HP:0001773
12 poor suck64 hallmark (90%) HP:0002033
13 polyphagia64 hallmark (90%) HP:0002591
14 short palm64 54 hallmark (90%) Frequent (79-30%) HP:0004279
15 narrow palm64 hallmark (90%) HP:0004283
16 short stature64 54 hallmark (90%) Frequent (79-30%) HP:0004322
17 cryptorchidism64 54 85% Frequent (79-30%) HP:0000028
18 attention deficit hyperactivity disorder64 common (75%) HP:0007018
19 scrotal hypoplasia64 69% HP:0000046
20 adrenal insufficiency64 60% HP:0000846
21 primary amenorrhea64 56% HP:0000786
22 micropenis64 typical (50%) HP:0000054
23 clitoral hypoplasia64 typical (50%) HP:0000060
24 hypoplastic labia minora64 typical (50%) HP:0000064
25 thin upper lip vermilion64 typical (50%) HP:0000219
26 narrow forehead64 typical (50%) HP:0000341
27 narrow nasal bridge64 typical (50%) HP:0000446
28 delayed puberty64 typical (50%) HP:0000823
29 cutaneous photosensitivity64 typical (50%) HP:0000992
30 nasal speech64 typical (50%) HP:0001611
31 recurrent respiratory infections64 typical (50%) HP:0002205
32 scoliosis64 54 typical (50%) Frequent (79-30%) HP:0002650
33 downturned corners of mouth64 54 typical (50%) Frequent (79-30%) HP:0002714
34 kyphosis64 typical (50%) HP:0002808
35 decreased muscle mass64 typical (50%) HP:0003199
36 almond-shaped palpebral fissure64 typical (50%) HP:0007874
37 sleep apnea64 typical (50%) HP:0010535
38 abnormality of the palate64 typical (50%) HP:0000174
39 microcephaly64 54 typical (50%) Frequent (79-30%) HP:0000252
40 strabismus64 54 typical (50%) Frequent (79-30%) HP:0000486
41 downslanted palpebral fissures64 54 typical (50%) Frequent (79-30%) HP:0000494
42 telecanthus64 54 typical (50%) Frequent (79-30%) HP:0000506
43 abnormality of dental enamel64 54 typical (50%) Frequent (79-30%) HP:0000682
44 behavioral abnormality64 54 typical (50%) Frequent (79-30%) HP:0000708
45 single transverse palmar crease64 typical (50%) HP:0000954
46 brachydactyly syndrome64 54 typical (50%) Frequent (79-30%) HP:0001156
47 seizures64 54 typical (50%) Frequent (79-30%) HP:0001250
48 muscular hypotonia64 54 typical (50%) Frequent (79-30%) HP:0001252
49 intrauterine growth retardation64 54 typical (50%) Frequent (79-30%) HP:0001511
50 incoordination64 typical (50%) HP:0002311
51 delayed skeletal maturation64 54 typical (50%) Frequent (79-30%) HP:0002750
52 abnormality of chromosome segregation64 typical (50%) HP:0002916
53 clinodactyly of the 5th finger64 54 typical (50%) Frequent (79-30%) HP:0004209
54 hypoplasia of penis64 54 typical (50%) Frequent (79-30%) HP:0008736
55 cognitive impairment64 typical (50%) HP:0100543
56 type i diabetes mellitus64 54 typical (50%) Frequent (79-30%) HP:0100651
57 hypoplasia of the ear cartilage64 54 typical (50%) Frequent (79-30%) HP:0100720
58 glomerulopathy64 54 typical (50%) Frequent (79-30%) HP:0100820
59 oligomenorrhea64 frequent (33%) HP:0000876
60 hypopigmentation of the skin64 frequent (33%) HP:0001010
61 ventriculomegaly64 frequent (33%) HP:0002119
62 hypopigmentation of hair64 frequent (33%) HP:0005599
63 impaired pain sensation64 frequent (33%) HP:0007328
64 iris hypopigmentation64 frequent (33%) HP:0007730
65 type ii diabetes mellitus64 25% HP:0005978
66 autism64 19% HP:0000717
67 psychosis64 15% HP:0000709
68 hip dysplasia64 10% HP:0001385
69 myopia64 occasional (7.5%) HP:0000545
70 esotropia64 occasional (7.5%) HP:0000565
71 upslanted palpebral fissure64 occasional (7.5%) HP:0000582
72 carious teeth64 occasional (7.5%) HP:0000670
73 osteopenia64 occasional (7.5%) HP:0000938
74 osteoporosis64 occasional (7.5%) HP:0000939
75 syndactyly64 occasional (7.5%) HP:0001159
76 frontal upsweep of hair64 occasional (7.5%) HP:0002236
77 temperature instability64 occasional (7.5%) HP:0005968
78 poor fine motor coordination64 occasional (7.5%) HP:0007010
79 radial deviation of finger64 occasional (7.5%) HP:0009466
80 precocious puberty64 4% HP:0000826
81 hypogonadism64 HP:0000135
82 intellectual disability64 54 Frequent (79-30%) HP:0001249
83 truncal obesity64 HP:0001956
84 feeding difficulties in infancy64 HP:0008872
85 dolichocephaly64 HP:0000268
86 hypermetropia64 HP:0000540
87 hyperinsulinemia64 HP:0000842
88 decreased fetal movement64 HP:0001558
89 hypoventilation64 HP:0002791
90 poor gross motor coordination64 HP:0007015
91 generalized hypopigmentation64 HP:0007513
92 abdominal obesity64 HP:0012743
93 clinodactyly64 HP:0030084
94 high palate54 Frequent (79-30%)
95 ataxia54 Frequent (79-30%)
96 bilateral single transverse palmar creases54 Frequent (79-30%)
97 abnormal hair pattern54 Frequent (79-30%)

MGI Mouse Phenotypes related to Prader-Willi Syndrome according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053759.7GHRL, IGF1, LEP, MAGEL2, OXT, PYY
2MP:00053868.4GABRA5, GABRB3, GHRL, LEP, MAGEL2, NDN

Drugs & Therapeutics for Prader-Willi Syndrome

About this section

Drugs for Prader-Willi Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 63)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
LiraglutideapprovedPhase 4, Phase 3315204656-20-2
Synonyms:
204656-20-2
Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
C439759
Liraglutida
Liraglutida [INN-Spanish]
Liraglutide
Liraglutide [USAN:INN]
Liraglutide recombinant
Liraglutidum
Liraglutidum [INN-Latin]
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide
 
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide
NN 2211
NN-2211
NN2211
NNC 90-1170
N²⁶-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptide
N²⁶-(hexadecanoyl-gamma-glutamyle)-[34-arginine]GLP-1-(7-37)-peptide
UNII-839I73S42A
Victoza
nn 2211
nn2211
victoza
2Hormone AntagonistsPhase 4, Phase 312778
3Hypoglycemic AgentsPhase 4, Phase 35733
4IncretinsPhase 4, Phase 31537
5Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 312767
6HormonesPhase 4, Phase 313979
7
Rimonabantapproved, investigationalPhase 345168273-06-1, 158681-13-1104850
Synonyms:
168273-06-1
5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide
5-(p-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidinopyrazole-3-carboxamide
A 281
AC-163720
AC-731
AC1L2XM5
Acomplia
Acomplia (TN)
C14319
CHEMBL111
CID104850
D05731
DB06155
I06-0381
L000572
LS-128155
 
MolPort-003-850-185
NCGC00164572-01
Rimonabant
Rimonabant (JAN/USAN/INN)
Rimonabant [USAN:INN]
Rimoslim
Riobant
SR 141716
SR 141716A
SR-141716
SR-141716A
SR141,716A
SR141716
SR141716A
STK642500
Slimona
UNII-RML78EN3XE
ZINC01540228
[3H]SR141716A
nchembio.129-comp21
nchembio.552-comp16
8
Oxytocinapproved, vet_approvedPhase 2, Phase 3, Phase 140850-56-6439302, 53477758
Synonyms:
(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
(Arg8)-Vasopressin
(Arg8)-Vasotocin
1-({(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-(4-hydroxybenzyl)-13-[(1S)-1-methylpropyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-leucylglycinamide
50-56-6
AC1L9735
Argipressin
Argpressin Acetate
BCBcMAP01_000094
Biotinyl-(Arg8)-Vasopressin
C00746
CHEBI:492195
CHEBI:7872
CHEMBL395429
CID439302
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Arg-Gly-NH2
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2
Cys-Tyr-Ile-Thr-Asn-Cys-Gly-Leu-Gly-NH2
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2
D00089
Disulfide bridge Cys1-Cys6
Gly-Leu-Pro-c
HS-2021
 
L-Cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucylglycinamide cyclic(1-6)-disulfide
MolPort-003-938-941
NCGC00167132-01
O3251_SIGMA
O4375_SIGMA
OXT
OXYTOCIN
Ocytocin
Oxitocina
Oxytocic hormone
Oxytocin (JP15/USP/INN)
Oxytocin (TN)
Oxytocin 10 Usp Units In Dextrose 5%
Oxytocin 20 Usp Units In Dextrose 5%
Oxytocin 5 Usp Units In Dextrose 5%
Oxytocin Acetate
Oxytocin injection
Oxytocine
Oxytocinum
Pitocin
Pitocin (TN)
Syntocinon
Syntocinon (TN)
TI-001
alpha-Hypophamine
nchembio.184-comp2
9
TopiramateapprovedPhase 324797240-79-45284627
Synonyms:
-D-fructopyranose deriv.
.beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate (9CI)
2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene) .beta.-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-36-D-fructo-pyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
2,3:4,5-Di- O -isopropylidene-(beta)-D-fructopyranose sulfamate
2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate
5H-Bis[1,3]dioxolo[4,5-b:4',5'-d]pyran, .beta.
97240-79-4
AKOS000424547
BIDD:GT0854
BIDD:PXR0127
BRN 5988957
BSPBio_002306
C052342
C07502
C12H21NO8S
CBChromo1_000352
CHEBI:129573
CHEMBL220492
CID5284627
CPD000466325
Cilag brand of topiramate
D00537
DB00273
Epitoma
Epitomax
HMS1922H06
HMS2051L09
HMS2093D20
HSDB 7531
Janssen brand of topiramate
KS-1122
KW-6485
LS-187392
LS-69764
MLS000759431
MLS001424070
McN 4853
McN-4853
MolPort-001-615-062
MolPort-002-885-869
NCGC00178714-01
 
Ortho brand of topiramate
RWJ 17021
RWJ-17021
RWJ-17021-000
S1438_Selleck
SAM001246601
SMR000466325
SPBio_000995
SPECTRUM1505801
STOCK1N-71037
Spectrum2_001128
T0575_SIGMA
TL8006021
TOR
TPM
Tipiramate
Tipiramate [French]
Tipiramato
Tipiramato [Spanish]
Topamac
Topamax
Topamax (TN)
Topamax Sprinkle
Topamax, Topiramate
Topimax
Topina
Topiramate
Topiramate (JAN/USAN/INN)
Topiramate (TPM)
Topiramate / Placebo
Topiramate [USAN:BAN:INN]
Topiramato
Topiramato [INN-Spanish]
Topiramatum
Topiramatum [INN-Latin]
Topiramic acid
Topomax
UNII-0H73WJJ391
USL-255
[(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate
beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate
beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, 1-sulfamate
topiramate
topiramate tablet
topiramatum [Latin]
10
Octreotideapproved, investigationalPhase 321383150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
 
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
11
SomatostatinapprovedPhase 322938916-34-6, 51110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
12Neurotransmitter AgentsPhase 317734
13Cannabinoid Receptor AntagonistsPhase 349
14Antineoplastic Agents, HormonalPhase 35407
15Gastrointestinal AgentsPhase 3, Phase 1, Phase 28109
16OxytocicsPhase 2, Phase 3, Phase 1660
17Neuroprotective AgentsPhase 31672
18Protective AgentsPhase 37190
19AnticonvulsantsPhase 32620
20Anti-Obesity AgentsPhase 3411
21
DiazoxideapprovedPhase 1, Phase 222364-98-73019
Synonyms:
2H-1,2, 4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide
2H-1,2,4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide
364-98-7
7-Chloro-3-methyl-1lambda~4~,2,4-benzothiadiazin-1-ol 1-oxide
7-Chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido
7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido [Italian]
7-chloro-3-methyl-4H-1
AC1L1EZN
Aroglycem
BPBio1_000016
BRD-K73109821-001-05-2
BSPBio_000014
BSPBio_001307
BSPBio_002290
Bio1_000036
Bio1_000525
Bio1_001014
Bio2_000027
Bio2_000507
C06949
C8H7ClN2O2S
CAS-364-98-7
CBiol_001750
CHEBI:4495
CHEMBL181
CID3019
CPD000058392
D 9035
D00294
D003981
D9035_SIGMA
DB01119
Diazossido
Diazossido [DCIT]
Diazossido [Italian]
Diazoxide
Diazoxide (JAN/USP/INN)
Diazoxide [USAN:INN:BAN]
Diazoxido
Diazoxido [INN-Spanish]
Diazoxidum
Diazoxidum [INN-Latin]
Dizoxide
EINECS 206-668-1
EU-0100404
Eudemine
HMS1361B09
HMS1568A16
HMS1791B09
HMS1922L22
HMS1989B09
HMS2051P20
HMS2089L04
HMS2093N12
Hyperstat
Hyperstat (TN)
Hypertonalum
I06-2041
 
IDI1_033777
KBio2_000027
KBio2_002595
KBio2_005163
KBio3_000053
KBio3_000054
KBio3_001510
KBioGR_000027
KBioGR_001776
KBioSS_000027
LS-40410
Lopac-D-9035
Lopac0_000404
MLS000028459
MLS001076071
MolPort-003-666-772
MolPort-003-941-186
Mutabase
NCGC00015380-01
NCGC00015380-02
NCGC00015380-03
NCGC00015380-05
NCGC00015380-12
NCGC00024907-01
NCGC00024907-02
NCGC00024907-03
NCGC00024907-04
NCGC00024907-05
NCGC00024907-06
NCGC00024907-07
NCGC00024907-08
NSC 64198
NSC 76130
NSC-64198
NSC64198
NSC76130
Prestwick0_000087
Prestwick1_000087
Prestwick2_000087
Prestwick3_000087
Prestwick_163
Proglicem
Proglycem
SAM001246872
SMR000058392
SPBio_001953
SPECTRUM2300206
SRG 95213
SRG-95213
Sch 6783
Sch-6783
Spectrum3_000735
Spectrum4_001248
Tocris-0964
UNII-O5CB12L4FN
VU0239714-6
ZINC03872277
diazoxide
nchembio.150-comp49
nchembio.476-comp10
22
Cholineapproved, nutraceuticalPhase 1, Phase 214862-49-7305
Synonyms:
(2-Hydroxyethyl)trimethyl ammonium
(2-Hydroxyethyl)trimethylammonium
(beta-hydroxyethyl)trimethylammonium
2-Hydroxy-N,N,N-trimethyl-ethanaminium
2-Hydroxy-N,N,N-trimethylethanaminium
Bilineurine
Biocolina
Biocoline
Choline
Choline cation
 
Choline ion
Cholinum
Hepacholine
Hormocline
Lipotril
N,N,N-Trimethylethanol-ammonium
N,N,N-Trimethylethanolammonium
N,N,N-trimethylethanol-ammonium
N-trimethylethanolamine
Neocolina
Paresan
trimethylethanolamine
23Vasodilator AgentsPhase 1, Phase 23438
24AntimetabolitesPhase 1, Phase 211774
25Nootropic AgentsPhase 1, Phase 2701
26Hypolipidemic AgentsPhase 1, Phase 22721
27Lipid Regulating AgentsPhase 1, Phase 22702
28Antihypertensive AgentsPhase 1, Phase 24095
29Pharmaceutical SolutionsPhase 27793
30methionineNutraceuticalPhase 280
31
Exenatideapproved, investigational289141758-74-915991534
Synonyms:
141732-76-5
141758-74-9
286014-72-0
335149-21-8
AC 2993
AC 2993 LAR
AC 2993A
AC-2993
AC002993
AC2993
AC2993a
Bydureon
Byetta
 
C074031
CHEBI:490990
CHEMBL414357
Ex4 peptide
Exenatide
Exenatide Synthetic
Exenatide synthetic
Exendin 4
Exendin 4 (Heloderma suspectum)
Exendin-4
Extendin-4
LY2148568
Synthetic exendin-4
UNII-9P1872D4OL
32
Hydrocortisoneapproved, vet_approved64050-23-75754, 657311
Synonyms:
(11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione
(11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
11-Hydrocortisone
11-beta-Hydrocortisone
11-beta-Hydroxycortisone
11a-Hydroxycorticosterone
11alpha-Hydroxycorticosterone
11b,17,21-Trihydroxyprogesterone
11b-Hydrocortisone
11b-Hydroxycortisone
11beta,17,21-Trihydroxyprogesterone
11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
11beta-Hydrocortisone
11beta-Hydroxycortisone
11beta-hydrocortisone
11β-hydrocortisone
17-Hydroxycorticosterone
17a-Hydroxycorticosterone
17alpha-Hydroxycorticosterone
2v95
4-Pregnen-11beta,17alpha,21-triol-3,20-dione
4-Pregnene-11alpha,21-triol 3,20-dione
4-Pregnene-11b,17a,21-triol-3,20-dione
50-23-7
8056-08-4
80562-38-5
8063-42-1
AC-12902
AC1L1L2B
ACETASOL HC
ACETIC ACID W/ HYDROCORTISONE
AI3-25006
AKOS001582651
Acticort
Acticort (TN)
Aeroseb HC
Aeroseb-HC
Ala-Cort
Ala-Scalp
Alacort
Algicirtis
Alphaderm
Amberin
Anflam
Anti-inflammatory hormone
Anucort
Anucort-HC
Anusol HC
Anusol HC (TN)
Aquacort
Aquanil HC
B48448A1-24BA-47CA-8D9E-43E5BC949386
BPBio1_000544
BRD-K93568044-001-03-1
BSPBio_000494
Balneol-hc
Barseb HC
Basan-Corti
Beta-hc
Bio-0648
C00735
C21H30O5
CCRIS 5854
CHEBI:17650
CHEMBL389621
CID5754
COR-OTICIN
CPD000653523
CaldeCORT Spray
Cetacort
Chronocort
Clear aid
Cleiton
Cobadex
Colocort
Colocort (TN)
Compound F
Compound F (kendall)
Cor-Tar-Quin
Corhydron
Cort-Dome
Cort-Quin
Cortanal
Cortef
Cortef (TN)
Cortenema
Cortesal
Corticreme
Cortifair
Cortifan
Cortifoam
Cortiment
Cortisol
Cortisol alcohol
Cortisol, Hydrocortisone
Cortisolonum
Cortisporin
Cortisporin Otico
Cortispray
Cortizol
Cortolotion
Cortonema
Cortoxide
Cortril
Cremesone
Cremicort-H
Cutisol
Cyclodextrin-encapsulated hydrocortisone
D00088
DB00741
DB07886
Delacort
Derm-Aid
Dermacort
Dermaspray
Dermil
Dermocortal
Dermolate
Dihydrocostisone
Dioderm
Dome-cort
Domolene-HC
Drotic
DuoCort
EINECS 200-020-1
EU-0100594
Ef corlin
Efcorbin
Efcortelan
Efcortelin
Eldecort
Eldercort
Epicort
Epicortisol
Epiderm H
Esiderm H
Evacort
Ficortril
Fiocortril
Flexicort
Foille Insetti
Genacort
Genacort (lotion)
Glycort
Gyno-Cortisone
H 4001
H-Cort
H0135_SIGMA
H0396_SIGMA
H0888_SIGMA
H3160_SIGMA
H4001_SIGMA
H6909_SIGMA
HC
HC #1
 
HC #4
HC (HYDROCORTISONE)
HMS1569I16
HMS2090M04
HSDB 3339
HYDROCORTISONE AND ACETIC ACID
HYDROCORTISONE IN ABSORBASE
Heb Cort
Heb-Cort
Hi-cor
Hidalone
Hidro-Colisona
Hidrocortisona
Hidrocortisona [INN-Spanish]
Hycort
Hycortol
Hycortole
Hydracort
Hydrasson
Hydro-Adreson
Hydro-Colisona
Hydro-RX
Hydro-colisona
Hydrocort
Hydrocortal
Hydrocorticosterone
Hydrocortisone
Hydrocortisone (JP15/USP/INN)
Hydrocortisone Acetate
Hydrocortisone Base
Hydrocortisone Butyrate
Hydrocortisone Sodium Phosphate
Hydrocortisone Valerate
Hydrocortisone [INN:BAN:JAN]
Hydrocortisone alcohol
Hydrocortisone base
Hydrocortisone free alcohol
Hydrocortisone solution
Hydrocortisone-Water Soluble
Hydrocortisonum
Hydrocortisonum [INN-Latin]
Hydrocortistab
Hydrocortisyl
Hydrocortone
Hydroskin
Hydroxycortisone
Hysone
Hytisone
Hytone
Hytone (TN)
Hytone lotion
Idrocortisone
Idrocortisone [DCIT]
Incortin-H
Incortin-hydrogen
Kendall'S compound F
Kendall's compound F
Komed HC
Kyypakkaus
LMST02030001
LS-7439
Lacticare HC
Lacticare-HC
Lactisona
Lopac0_000594
Lubricort
MLS000069609
MLS001148103
MLS002207135
MLS002222189
Maintasone
Medicort
Meusicort
Mildison
Milliderm
MolPort-001-794-637
NCGC00022848-06
NCGC00022848-07
NCGC00022848-09
NCGC00022848-12
NCI60_000118
NSC 10483
NSC-10483
NSC10483
Neo-Cort-Dome
Neo-Cortef
Neosporin-H Ear
Nogenic HC
Nutracort
Nystaform-HC
ORLEX HC
Optef
Otalgine
Otic-Neo-Cort-Dome
Otobiotic
Otocort
Otosone-F
Pediotic Suspension
Penecort
Permicort
Polcort H
Preparation H Hydrocortisone Cream
Prepcort
Prestwick0_000447
Prestwick1_000447
Prestwick2_000447
Prestwick3_000447
Prestwick_265
Prevex HC
Proctocort
Proctofoam
Proctozone HC
Protocort
Racet
Rectasol-HC
Rectoid
Reichstein'S substance M
Reichstein's substance M
Remederm HC
S1696_Selleck
SAM002264617
SMP1_000156
SMR000059022
SMR000653523
SPBio_002433
Sanatison
Scalp-Cort
Scalpicin Capilar
Schericur
Scheroson F
Sigmacort
Signef
Stie-cort
Stiefcorcil
Synacort
Systral Hydrocort
Tarcortin
Texacort
Texacort lotion 25
Timocort
Topicort
Transderma H
Traumaide
UNII-WI4X0X7BPJ
UPCMLD-DP133
UPCMLD-DP133:001
Uniderm
Vioform-Hydrocortisone
VoSol HC
Vytone
Zenoxone
[3H]cortisol
component of Lubricort
component of Neo-Cort-Dome
component of Otalgine
hydrocortisone
33
Metyraponeapproved1254-36-44174
Synonyms:
1,2-Di-3-pyridyl-2-methyl-1-propanone
2-Methyl-1,2-bis(3-pyridyl)-1-propanone
2-Methyl-1,2-di-3-pyridinyl-1-propanone
2-Methyl-1,2-di-3-pyridyl-1-propanone
2-methyl-1,2-dipyridin-3-yl-propan-1-one
2-methyl-1,2-dipyridin-3-ylpropan-1-one
37245-80-0
4885, SU
54-36-4
856525_ALDRICH
AB00513955
AC1L1HKV
AC1Q1LHX
Alliance Brand of Metyrapone
BIDD:PXR0082
BPBio1_000824
BRD-K46862739-001-03-6
BSPBio_000748
C07205
C14H14N2O
CAS-54-36-4
CHEBI:44241
CHEMBL934
CID4174
CPD-7023
CPD000059134
D00410
D008797
DB01011
EINECS 200-206-2
EU-0009322
HMS1570F10
HMS2094I07
HSDB 2500
LS-123097
METOPIRONE (TN)
MLS001066377
MLS001335881
MLS001335882
MYT
 
Mepyrapone
Metapirone
Metapyron
Methapyrapone
Methbipyranone
Methopirapone
Methopyrapone
Methopyrinine
Methopyrone
Metirapona
Metirapona [INN-Spanish]
Metopiron
Metopirone
Metopyrone
Metroprione
Metyrapon
Metyrapone
Metyrapone (JP15/USP/INN)
Metyrapone Alliance Brand
Metyrapone Novartis Brand
Metyrapone [USAN:INN:BAN:JAN]
Metyraponum
Metyraponum [INN-Latin]
MolPort-001-794-644
NCGC00016242-01
NCGC00161837-01
NSC 25265
NSC25265
Novartis Brand of Metyrapone
Prestwick0_000904
Prestwick1_000904
Prestwick2_000904
Prestwick3_000904
SAM002297829
SMR000059134
SPBio_002947
ST51006925
Su 4885
Su-4885
UNII-ZS9KD92H6V
ZINC00001728
metyrapone
34
Epinephrineapproved, vet_approved93351-43-45816
Synonyms:
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-dihydroxy-a-[(methylamino)methyl]-Benzyl alcohol
(-)-3,4-dihydroxy-alpha-[(methylamino)methyl]-Benzyl alcohol
(-)-Adrenalin
(-)-Adrenaline
(-)-Epinephrine
(-)-R-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-(−)-adrenaline
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-4-[1-hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
(R)-Adrenaline
(R)-Epinephrine
(−)-adrenaline
02252_FLUKA
1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
1-Adrenalin
1-Epinephrine
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
51-43-4
51-43-4 (FREE BASE)
51028-73-0
A0173
AC-13188
AC1L1L7B
ADR ADRENALINE
ADROP
AI3-19015
Adnephrine
Adrenal
Adrenalin
Adrenalin (TN)
Adrenalin in Oil
Adrenalin-Medihaler
Adrenalina
Adrenalina [DCIT]
Adrenaline
Adrenaline (JP15)
Adrenaline/Epinephrine
Adrenalinum
Adrenamine
Adrenan
Adrenapax
Adrenasol
Adrenatrate
Adrenine
Adrenodis
Adrenohorma
Adrenosan
Adrenutol
Adrin
Adrine
Ana-Guard
Ana-Kit
Antiasthmatique
Asmatane Mist
Asthma meter mist
Asthma-nefrin
Asthmahaler Mist
Asthmanefrin
Astmahalin
Astminhal
BIDD:GT0119
Balmadren
Bernarenin
Biorenine
Bosmin
Brevirenin
Bronkaid
Bronkaid Mist
Bronkaid Suspension Mist
Bupivacaine Hcl and Epinephrine
C00788
CCRIS 4812
CHEBI:28918
CHEMBL679
CID5816
Chelafrin
Citanest Forte
Corisol
D-Epifrin
D-Epinephrine
D00095
DB00668
Drenamist
Dylephrin
Dyspne-Inhal
E4250_SIGMA
EINECS 200-098-7
EPI E Z PEN JR
EPIPEN E Z PEN
EPIPEN JR
Epi EZ Pen Jr
Epifrin
Epiglaufrin
Epinefrin
Epinefrin [Czech]
Epinefrina
Epinefrina [INN-Spanish]
Epinephran
Epinephrin
Epinephrine
Epinephrine (USP)
Epinephrine (USP/INN)
Epinephrine [USAN:INN:JAN]
Epinephrine hydrochloride
Epinephrinum
Epinephrinum [INN-Latin]
Epipen
Epipen (TN)
Epipen Auto-Injector
Epipen EZ Pen
Epipen Jr.
Epipen Jr. Auto-Injector
Epirenamine
Epirenan
Epirenin
Epitrate
Eppy
Esphygmogenina
Exadrin
 
Glaucon
Glaucosan
Glauposine
Glycirenan
HSCI1_000215
HSDB 4289
Haemostasin
Haemostatin
Hektalin
Hemisine
Hemostasin
Hemostatin
Hypernephrin
Hyporenin
IOP
Intranefrin
Iontocaine
Isoptoepinal
Kidoline
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-Adrenaline Base
L-Epinehphrine
L-Epinephrine
L-Epirenamine
L-Methylaminoethanolcatechol
L-epinephrine
LS-156
Levo-Methylaminoethanolcatechol
Levoadrenaline
Levoepinephrine
Levorenen
Levorenin
Levorenine
Levoreninum
Lopac-E-4642
Lyodrin
Lyophrin
Medihaler-Epi
Metanephrin
Methylaminoethanolcatechol
Methylarterenol
Micronefrin
Micronephrine
MolPort-002-051-368
Mucidrina
Myosthenine
Mytrate
NCGC00015417-01
NCGC00142615-01
NCGC00142615-03
NCGC00142615-04
NCGC00142615-05
NCGC00142615-06
NCGC00142615-07
NSC 62786
NSC62786
Nephridine
Nieraline
PDSP1_001120
PDSP2_001104
Paranephrin
Primatene
Primatene Mist
R-(-)-Epinephrine
R-Adrenaline
RCRA waste no. P042
Racemic Epinephrine
Racepinephrine
Rcra waste number P042
Renagladin
Renaglandin
Renaglandulin
Renaleptine
Renalina
Renoform
Renostypricin
Renostypticin
Renostyptin
SMP1_000227
ST069368
SUS-PHRINE SULFITE-FREE
Scurenaline
Septocaine
Simplene
Sindrenina
Soladren
Sphygmogenin
Stryptirenal
Styptirenal
Supracapsulin
Supradin
Supranefran
Supranephrane
Supranephrine
Supranol
Suprarenaline
Suprarenin
Suprel
Surenine
Surrenine
Sus-Phrine
Sus-phrine
Susphrine
Sympathin I
Takamina
Takamine
Tokamina
Tonogen
Twinject
Twinject 0.15
Twinject 0.3
Twinject 0.30
UNII-YKH834O4BH
Vaponefrin
Vasoconstrictine
Vasoconstrictor
Vasodrine
Vasoton
Vasotonin
adrenaline
bmse000316
d-Adrenaline
epinephrine
l-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
l-Adrenalin
l-Adrenaline
l-Epinephine
l-Epinephrine (synthetic)
l-Epirenamine
l-Methylaminoethanolcatechol
levoepinephrine
nchembio747-comp9
35
Cosyntropinapproved2416960-16-016129617
Synonyms:
16960-16-0
ATCH (1-24)
Adrenocorticotropic hormone fragment 1-24 human, rat
COSYNTROPIN
Corticotropin tetracosapeptide
Cortrosyn
Cortrosyn (TN)
Cosyntropin
Cosyntropin (USAN)
 
D00284
Tetracosactide
Tetracosactide (INN)
Tetracosactrin
adrenocorticotropic hormone 1-24
alpha(1-24)-corticotrophin
beta(1-24)-corticotrophin
corticotropin-(1-24)
corticotropin-(1-24) tetracosapeptide
α1-24-corticotrophin
β1-24-corticotrophin
36
Anastrozoleapproved, investigational272120511-73-12187
Synonyms:
.alpha.,alpha.,.alpha.',.alpha.'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
1,3-benzenediacetonitrile, a, a, a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)
120511-73-1
2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile)
2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
AC-4234
AC1L1D49
Anastrazole
Anastrole
Anastrozol
Anastrozole (JAN/USAN/INN)
Anastrozole [USAN:INN:BAN]
Arimidex
Arimidex (TN)
Arimidex (Zeneca)
Arimidex, Anastrozole
Asiolex
Astra brand of anastrozole
AstraZeneca brand of anastrozole
C08159
C090450
C17H19N5
CHEBI:2704
CHEMBL1399
CID2187
CPD000466301
 
D00960
DB01217
HMS2052M11
HMS2089N10
HSDB 7462
I06-0021
ICI D1033
ICI-D 1033
ICI-D1033
LS-29563
MLS000759396
MLS001424217
MolPort-005-933-078
NCGC00164619-01
NSC719344
S1188_Selleck
SAM001246525
SBB066057
SMR000466301
UNII-2Z07MYW1AZ
ZD 1033
ZD-1033
ZD1033
ZINC00000941
Zeneca ZD 1033
Zeneca brand of anastrozole
alpha,alpha,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
anastrazole
anastrozole
37
Mentholapproved23532216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
38Glucagon-Like Peptide 1694
39Anesthetics9001
40Hydrocortisone acetate640
41Cortisol succinate640
42Liver Extracts3868
43Hydrocortisone 17-butyrate 21-propionate640
44insulin4524
45Insulin, Globin Zinc4523
46Mydriatics763
47Respiratory System Agents4818
48Vasoconstrictor Agents2027
49Racepinephrine933
50Peripheral Nervous System Agents22776

Interventional clinical trials:

(show top 50)    (show all 62)
idNameStatusNCT IDPhase
1Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome?CompletedNCT01298180Phase 4
2Oxygen Versus Medical Air for Treatment of CSA in Prader Will SyndromeRecruitingNCT03031626Phase 4
3Liraglutide Use in Prader-Willi SyndromeTerminatedNCT01542242Phase 4
4Effect of Rimonabant on Weight Gain and Body Composition in Adults With Prader Willi SyndromeUnknown statusNCT00603109Phase 3
5Growth Hormone Use in Adults With Prader-Willi SyndromeUnknown statusNCT00444964Phase 3
6Study of the Efficacy of Topiramate in Patients With Prader Willi Syndrome Over 8 WeeksCompletedNCT02810483Phase 3
7Effects of Intranasal Administration of Oxytocin in Adults With Prader-Willi SyndromeRecruitingNCT02804373Phase 2, Phase 3
8Study to Assess the Efficacy and Safety of Eutropin in Prader-Willi SyndromeRecruitingNCT02204163Phase 3
9Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi SyndromeRecruitingNCT02527200Phase 3
10Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi SyndromeTerminatedNCT02179151Phase 3
11Prader-Willi Syndrome and AppetiteTerminatedNCT00175305Phase 3
12Ph 2 Trial to Evaluate Safety & Efficacy of RM-493 in Obese Patients With Prader-Willi SyndromeCompletedNCT02311673Phase 2
13Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi SyndromeCompletedNCT02034071Phase 1, Phase 2
14Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi SyndromeCompletedNCT01968187Phase 2
15Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot ProjectCompletedNCT00742664Phase 1, Phase 2
16An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi SyndromeCompletedNCT01818921Phase 2
17Comparative Study Between Prader-Willi Patients Who Take Oxytocin Versus PlaceboCompletedNCT01038570Phase 2
18Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS InfantsCompletedNCT02205034Phase 1, Phase 2
19Tolerance of Intranasal Administration of OT in Prader-Willi Newborn BabiesCompletedNCT01548521Phase 1, Phase 2
20Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi SyndromeRecruitingNCT02629991Phase 2
21Cannabidiol Oral Solution for The Treatment of Subjects With Prader-Willi SyndromeNot yet recruitingNCT02844933Phase 2
22A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR)Not yet recruitingNCT02893618Phase 2
23Deep Brain Stimulation for the Treatment of Obesity in Patients With Prader-Willi SyndromeUnknown statusNCT02297022Phase 1
24Oxytocin Trial in Prader-Willi SyndromeCompletedNCT02013258Phase 1
25Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult VolunteersCompletedNCT01401244Phase 1
26Parents Resources for Decreasing the Incidence of Change Triggered Temper OutburstsActive, not recruitingNCT02567357Phase 1
27Experience With Growth Hormone (GH) in Children Under 2 Years With Prader-Willi Syndrome (PWS) in the Pediatric Endocrine Department of the Hospital of SabadellUnknown statusNCT02205450
28Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi SyndromeUnknown statusNCT00551343
29Family-based Intervention for Youth With Prader-Willi Syndrome: The Active Play at Home StudyUnknown statusNCT02058342
30Exploring Stress and Coping Behaviors of the Major Carer Whose Children With Prader-Willi SyndromeUnknown statusNCT00808548
31PREPL in Health and DiseaseUnknown statusNCT02263781
32Hypoglycemia in Prader-Willi SyndromeCompletedNCT01897363
33Characteristics of Prader-Willi Syndrome and Early-onset Morbid ObesityCompletedNCT00375089
34Treatment of Self-Injurious Behavior in Individuals With Prader-Willi SyndromeCompletedNCT00065923
35Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi SyndromeCompletedNCT00705172
36Plasma Adiponectin Level and Vascular Endothelial and Smooth Muscle Cell Function in Children With Prader-Willi SyndromeCompletedNCT01479322
37Plasma Adiponectin Level and Sleep Structures in Children With Prader-Willi SyndromeCompletedNCT01622751
38Cortisol Activity in Patients With Prader-Willi Syndrome and Healthy ControlsCompletedNCT00932932
39Effects of Exenatide on Overweight Adolescents With Prader-Willi SyndromeCompletedNCT01444898
40Increased Expression of Adiponectin Receptor 2 in the Mononuclear Cells in Children With Prader-Willi SyndromeCompletedNCT00800852
41Nordic Study on the Effects of Growth Hormone (Norditropin SimpleXx) Treatment in Adults With Prader-Willi SyndromeCompletedNCT00372125
42Prader-Willi Syndrome Macronutrient StudyCompletedNCT02011360
43The Intestinal Function in People With Prader-Willi SyndromeCompletedNCT01523288
44Ghrelin Suppression by Octreotide in Prader-WilliCompletedNCT01613495
45Correlation of Hyperghrelinemia With Carotid Artery Intima-Media Thickness in Children With Prader-Willi SyndromeCompletedNCT00474643
46Characterization of Transcriptional Regulators of Ghrelin Hormone Which Causes Genetic ObesityCompletedNCT01404624
47Macronutrient Regulation of Ghrelin and Peptide YYCompletedNCT02464514
48Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PWCompletedNCT02670694
49Brain-Derived Neurotrophic Factor in Obesity and Brain FunctionCompletedNCT01517048
50Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion SyndromesCompletedNCT00004351

Search NIH Clinical Center for Prader-Willi Syndrome


Cochrane evidence based reviews: prader-willi syndrome

Genetic Tests for Prader-Willi Syndrome

About this section

Genetic tests related to Prader-Willi Syndrome:

id Genetic test Affiliating Genes
1 Prader-Willi Syndrome27 24

Anatomical Context for Prader-Willi Syndrome

About this section

MalaCards organs/tissues related to Prader-Willi Syndrome:

36
Skin, Brain, Testes, Bone, Endothelial, Liver, Smooth muscle

Publications for Prader-Willi Syndrome

About this section

Articles related to Prader-Willi Syndrome:

(show top 50)    (show all 796)
idTitleAuthorsYear
1
Deficiency in prohormone convertase PC1 impairs prohormone processing in Prader-Willi syndrome. (27941249)
2017
2
Impaired prohormone processing: a grand unified theory for features of Prader-Willi syndrome? (27941250)
2017
3
Cognition in people with Prader-Willi syndrome: Insights into genetic influences on cognitive and social development. (27836461)
2017
4
Targeting the histone methyltransferase G9a activates imprinted genes and improves survival of a mouse model of Prader-Willi syndrome. (28024084)
2016
5
A boy with Prader-Willi syndrome: unmasking precocious puberty during growth hormone replacement therapy. (27982202)
2016
6
Mechanisms of obesity in Prader-Willi syndrome. (27863129)
2016
7
Baroreflex Dysfunction in Prader Willi Syndrome. (27134867)
2016
8
Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe. (27038627)
2016
9
Prader Willi Syndrome: Genetics, Metabolomics, Hormonal Function, and New Approaches to Therapy. (27426895)
2016
10
Association between physical activity and bone in children with Prader-Willi syndrome. (27159915)
2016
11
Microscopic structure of dental hard tissues in primary and permanent teeth from individuals with Prader-Willi syndrome. (26913968)
2016
12
Zebrafish Models of Prader-Willi Syndrome: Fast Track to Pharmacotherapeutics. (27857842)
2016
13
High unacylated ghrelin levels support the concept of anorexia in infants with prader-willi syndrome. (27146407)
2016
14
Deactivation of the left dorsolateral prefrontal cortex in Prader-Willi syndrome after meal consumption. (27121248)
2016
15
Weight control and behavior rehabilitation in a patient suffering from Prader Willi syndrome. (27036220)
2016
16
Prader-Willi Syndrome due to an Unbalanced de novo Translocation t(15;19)(q12;p13.3). (27894106)
2016
17
Prader-Willi syndrome and atypical submicroscopic 15q11-q13 deletions with or without imprinting defects. (27659713)
2016
18
Nutritional intervention with hypocaloric diet for weight control in children and adolescents with Prader-Willi Syndrome. (26970733)
2016
19
Higher plasma orexin a levels in children with Prader-Willi syndrome compared with healthy unrelated sibling controls. (27518917)
2016
20
Prader-Willi Syndrome, Management of Impulsivity, and Hyperphagia in an Adolescent. (27028699)
2016
21
A Rare Association of Obesity, Diabetes Mellitus and Bilateral Cryptorchidism: Prader - Willi Syndrome. (27805351)
2016
22
Reply to Letter to the Editor: Acylated and unacylated ghrelin during OGTT in Prader-Willi syndrome, a rebuttal to the conclusions by Kuppens et al. (27144882)
2016
23
Ambient temperature modulates the effects of the Prader-Willi syndrome candidate gene Snord116 on energy homeostasis. (27823858)
2016
24
Increased alternate splicing of Htr2c in a mouse model for Prader-Willi syndrome leads disruption of 5HT2C receptor mediated appetite. (27931246)
2016
25
Disorders of glucose metabolism in Prader-Willi syndrome: Results of a multicenter Italian cohort study. (27381990)
2016
26
Life Satisfaction Among Mothers of Individuals with Prader-Willi Syndrome. (26883647)
2016
27
Indices of Adiposity by Weight Status in Children With and Without Prader-Willi Syndrome: 3670 Board #109 June 4, 8: 00 AM - 9: 30 AM. (27362036)
2016
28
Drug-induced sleep endoscopy in children with Prader-Willi syndrome. (27059377)
2016
29
Aripiprazole in the Treatment of Obsessive Compulsive Disorder and Aggressive Behaviors in a Child With Prader Willi Syndrome: A Case Report. (27518476)
2016
30
Use of a venting PEG tube in the management of recurrent acute gastric dilatation associated with Prader-Willi syndrome. (26763981)
2016
31
Economic burden and health-related quality of life associated with Prader-Willi syndrome in France. (27174598)
2016
32
Elevated plasma oxytocin levels in children with Prader-Willi syndrome compared with healthy unrelated siblings. (26615966)
2016
33
Deficits in voice and multisensory processing in patients with Prader-Willi syndrome. (26994593)
2016
34
Respiratory Complications in Children with Prader Willi Syndrome. (27839656)
2016
35
Beneficial effects of growth hormone in young adults with Prader-Willi syndrome: a 2-year cross-over trial. (27552545)
2016
36
Dysfunctional oleoylethanolamide signaling in a mouse model of Prader-Willi syndrome. (28007570)
2016
37
Quality of life in children with Prader Willi Syndrome: Parent and child reports. (27433979)
2016
38
Response to letter to the editor by Scheimann, Miller, and Glaze: Laparoscopic sleeve gastrectomy in children and adolescents with Prader-Willi Syndrome: A matched control study. (27986576)
2016
39
Causes of death in Prader-Willi syndrome: Prader-Willi Syndrome Association (USA) 40-year mortality survey. (27854358)
2016
40
Cognitive and adaptive advantages of growth hormone treatment in children with Prader-Willi syndrome. (27481444)
2016
41
Adult Prader-Willi Syndrome: An Update on Management. (27375909)
2016
42
Anthropometric adjustments are helpful in the interpretation of BMD and BMC Z-scores of pediatric patients with Prader-Willi syndrome. (27377921)
2016
43
A mindfulness-based intervention for self-management of verbal and physical aggression by adolescents with Prader-Willi syndrome. (27019027)
2016
44
Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome. (27071367)
2016
45
Promising effects of oxytocin on social and food-related behaviour in young children with Prader-Willi syndrome: a randomized, double-blind, controlled crossover trial. (27486141)
2016
46
Higher plasma orexin A levels in children with Prader-Willi syndrome compared with healthy unrelated sibling controls. (27214028)
2016
47
Acylated and unacylated ghrelin during OGTT in Prader-Willi syndrome: A rebuttal to the conclusions by Kuppens et al. (27037909)
2016
48
Erratum: Postprandial metabolism in adults with prader-willi syndrome. (27460716)
2016
49
Clinical Application of an Innovative Multiplex-Fluorescent-Labeled STRs Assay for Prader-Willi Syndrome and Angelman Syndrome. (26841067)
2016
50
Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome. (27900261)
2016

Variations for Prader-Willi Syndrome

About this section

Copy number variations for Prader-Willi Syndrome from CNVD:

6 (show all 45)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1137421127800000DeletionPrader-willi syndrome
289246151700000023300000Copy numberSNRPNPrader-willi syndrome
389251151700000031400000Copy numberPrader-willi syndrome
489253151700000031400000Copy numberC15orf2Prader-willi syndrome
589254151700000031400000Copy numberNDNPrader-willi syndrome
689255151700000031400000Copy numberSNORDPrader-willi syndrome
789256151700000031400000Copy numberSNRPNPrader-willi syndrome
889261151700000031400000DeletionPrader-willi syndrome
989262151700000031400000DeletionPrader-willi syndrome
1089263151700000031400000DeletionPrader-willi syndrome
1189267151700000031400000DeletionUBE3APrader-willi syndrome
1289283151700000031400000DuplicationNDNPrader-willi syndrome
1389285151700000031400000DuplicationSNRPNPrader-willi syndrome
1489286151700000031400000DuplicationSNRPNPrader-willi syndrome
1589289151700000031400000DuplicationUBE3APrader-willi syndrome
1689290151700000031400000DuplicationUBE3APrader-willi syndrome
1789292151700000031400000Genomic rearrangemen tPrader-willi syndrome
1889294151700000031400000MicrodeletionPrader-willi syndrome
1989295151700000031400000MicrodeletionPrader-willi syndrome
2089296151700000031400000MicrodeletionPrader-willi syndrome
2189298151700000031400000MicrodeletionSNRPNPrader-willi syndrome
2289413151840000023300000DeletionPrader-willi syndrome
2389434151840000031400000DeletionPrader-willi syndrome
2489562151868300027286000DeletionPrader-willi syndrome
2589763151900000033600000Copy numberPrader-willi syndrome
2690357152148164621483543Copy numberNDNPrader-willi syndrome
2790510152261988622795318Copy numberSNRPNPrader-willi syndrome
2890529152283559423010179MicrodeletionHBII-85Prader-willi syndrome
2990530152283559423010179MicrodeletionSNURFPrader-willi syndrome
3090531152283559423010179MicrodeletionSNRPNPrader-willi syndrome
3190532152283559423010179MicrodeletionUBE3APrader-willi syndrome
3290759152313348823235221Copy numberUBE3APrader-willi syndrome
3391319152900000031400000MicrodeletionCHRNA7Prader-willi syndrome
3491774153347194135072476DeletionATPBD4Prader-willi syndrome
3591775153347194135072476DeletionCSNK1A1PPrader-willi syndrome
3691776153347194135072476DeletionMEIS2Prader-willi syndrome
37112051173780000041900000LossPrader-willi syndrome
38138424X152940457153016382DeletionMECP2Prader-willi syndrome
39160279221180000024300000Microdeletion or mic roduplicationPrader-willi syndrome
40161857222050000021800000LossPrader-willi syndrome
4119806251900000033600000DeletionPrader-willi syndrome
42203653612300000GainPrader-willi syndrome
4323933783850000039500000LossPrader-willi syndrome
44257160X14300000LossPrader-willi syndrome
45260244X146900000154913754LossPrader-willi syndrome

Expression for genes affiliated with Prader-Willi Syndrome

About this section
Search GEO for disease gene expression data for Prader-Willi Syndrome.

Pathways for genes affiliated with Prader-Willi Syndrome

About this section

GO Terms for genes affiliated with Prader-Willi Syndrome

About this section

Cellular components related to Prader-Willi Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1GABA-A receptor complexGO:190271110.0GABRA5, GABRB3

Biological processes related to Prader-Willi Syndrome according to GeneCards Suite gene sharing:

(show all 13)
idNameGO IDScoreTop Affiliating Genes
1adult feeding behaviorGO:000834310.7GHRL, LEP
2bone mineralization involved in bone maturationGO:003563010.7IGF1, LEP
3inner ear receptor cell developmentGO:006011910.6GABRA5, GABRB3
4innervationGO:006038410.6GABRA5, GABRB3
5positive regulation of insulin-like growth factor receptor signaling pathwayGO:004356810.6GH1, IGF1
6positive regulation of JAK-STAT cascadeGO:004642710.6GH1, LEP
7positive regulation of tyrosine phosphorylation of Stat5 proteinGO:004252310.6GH1, IGF1
8neuron developmentGO:004866610.5GABRA5, GABRB3, NDN
9female pregnancyGO:000756510.3IGF1, LEP, OXT
10eating behaviorGO:004275510.3LEP, OXT, PYY
11response to activityGO:001482310.2IGF1, LEP, OXT
12positive regulation of phosphatidylinositol 3-kinase signalingGO:001406810.2GH1, IGF1, LEP, UBE3A
13response to estradiolGO:00323559.7GH1, LEP, OXT

Molecular functions related to Prader-Willi Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1GABA-A receptor activityGO:000489010.5GABRA5, GABRB3
2hormone activityGO:00051799.4GH1, GHRL, IGF1, LEP, PYY

Sources for Prader-Willi Syndrome

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet